secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0000886163-25-000042
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand completes merger with Channel Therapeutics; Pelthos starts trading July 2 under PTHS
--------------------------------------------------------------------------------

- Ligand subsidiary merges with Channel; combined company renamed Pelthos Therapeutics, trading on NYSE American as PTHS.
- Ligand invests $18M in Pelthos; entitled to 13% royalty on worldwide net sales of ZELSUVMI.
- Pelthos raises total $50.1M equity from Ligand and Murchinson-led investor group.
- ZELSUVMI (berdazimer) topical gel, FDA-approved for molluscum, to launch July 2025; first at-home prescription treatment.
- Pelthos to also evaluate Channel's NaV 1.7 pain development programs for chronic pain and eye pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000042/0000886163-25-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000042/lgnd-20250702.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer